Suppr超能文献

医疗机构层面心房颤动抗凝治疗的种族差异:REACH-AF 研究。

Facility-Level Variation in Racial Disparities in Anticoagulation for Atrial Fibrillation: The REACH-AF Study.

机构信息

HSRD Center for the Study of Healthcare Innovation, Implementation & Policy, VA Greater Los Angeles VA Healthcare System, Los Angeles, CA, USA.

Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles, CA, USA.

出版信息

J Gen Intern Med. 2024 May;39(7):1122-1126. doi: 10.1007/s11606-024-08643-8. Epub 2024 Feb 2.

Abstract

BACKGROUND

Oral anticoagulation reduces stroke risk for patients with atrial fibrillation (AF). Prior research demonstrates lower anticoagulant prescribing in Black than in White individuals but few studies have examined racial differences in facility-level anticoagulant prescribing for AF.

OBJECTIVE

To assess variation in anticoagulant initiation by race within Veterans Health Administration (VA) facilities.

DESIGN

Retrospective cohort study.

PARTICIPANTS

Black and White patients enrolled in the VA with incident AF from 2020 through 2021.

MAIN MEASURES

The primary outcome was rate of any anticoagulant initiation (i.e., warfarin or direct oral anticoagulant [DOAC]) or any DOAC therapy within 90 days of an AF diagnosis, overall and for Black and White patients at each facility. We also estimated the adjusted Black-White risk difference.

KEY RESULTS

In 82 VA facilities serving 26,832 Black and White patients, overall unadjusted rates of any anticoagulant therapy ranged from 56.8 to 87.1% across facilities; the corresponding ranges for Black and White patients were 47.6 to 91.3% and 58.2 to 87.1%, respectively. Overall unadjusted rates of DOAC therapy ranged from 55.1 to 85.5% by facility; ranges for Black and White patients were 42.8 to 86.9% and 56.4 to 85.5%, respectively. The adjusted risk difference between Black and White patients ranged from - 29.9 (95% CI, - 54.9 to - 4.8) to 14.2 (95% CI, - 9.1 to 25.0) across facilities for any anticoagulant therapy and from - 28.8 (95% CI, - 58.3 to 0.8) to 15.0 (95% CI, - 8.0 to 38.1) for DOAC therapy. For any anticoagulant therapy there were 3 facilities where prescribing was statistically higher in White than Black patients; for DOAC therapy there were 5 such facilities.

CONCLUSIONS

In a national cohort of patients with AF, we observed large facility-level variation and adjusted risk differences in any anticoagulant and DOAC initiation, overall and by race. These findings represent a target for local quality improvement in AF care.

摘要

背景

口服抗凝剂可降低房颤(AF)患者的中风风险。先前的研究表明,黑人患者的抗凝药物处方率低于白人患者,但很少有研究检查 AF 治疗中医疗机构层面的种族差异。

目的

评估退伍军人事务部(VA)医疗机构中种族间抗凝药物起始的差异。

设计

回顾性队列研究。

参与者

2020 年至 2021 年期间,VA 中患有 AF 的黑人及白人患者。

主要措施

主要结局是在 AF 诊断后 90 天内,任何抗凝药物(即华法林或直接口服抗凝剂[DOAC])或任何 DOAC 治疗的起始率,总体而言以及每个机构的黑人和白人患者的起始率。我们还估计了调整后的黑白风险差异。

主要结果

在为 26832 名黑人和白人患者提供服务的 82 家 VA 机构中,整体未经调整的任何抗凝治疗率在机构间的范围为 56.8%至 87.1%;黑人和白人患者的相应范围分别为 47.6%至 91.3%和 58.2%至 87.1%。整体未经调整的 DOAC 治疗率在机构间的范围为 55.1%至 85.5%;黑人和白人患者的范围分别为 42.8%至 86.9%和 56.4%至 85.5%。任何抗凝治疗的黑人和白人患者之间的调整风险差异在机构间的范围为-29.9(95%置信区间,-54.9 至-4.8)至 14.2(95%置信区间,-9.1 至 25.0);DOAC 治疗的范围为-28.8(95%置信区间,-58.3 至 0.8)至 15.0(95%置信区间,-8.0 至 38.1)。对于任何抗凝治疗,有 3 家机构的白人患者的处方率明显高于黑人患者;对于 DOAC 治疗,有 5 家机构存在这种情况。

结论

在全国范围内的 AF 患者队列中,我们观察到总体和按种族分类的任何抗凝药物和 DOAC 起始的大型医疗机构间差异和调整后的风险差异。这些发现代表了 AF 治疗中当地质量改进的目标。

相似文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验